Stockscreener 앱 받기
5.89
6.47%
0.33
Verrica Pharmaceuticals Inc 주식(VRCA)의 최신 뉴스
Verrica Pharmaceuticals appoints Chris Chapman as chief commercial officer - marketscreener.com
Verrica Pharmaceuticals (VRCA) Appoints New Chief Commercial Off - GuruFocus
Verrica Pharmaceuticals Inc. Appoints Chris Chapman as Chief Commercial Officer - Quiver Quantitative
VTAMA launch leader joins Verrica to drive YCANTH skin treatment - Stock Titan
Verrica’s Japanese Market Debut: A Strategic Expansion Unfolds - AD HOC NEWS
Verrica’s partner launches molluscum treatment in Japan By Investing.com - Investing.com South Africa
Verrica announces launch of Ycanth in Japan by Torii - The Pharma Letter
Verrica Pharmaceuticals stock rises after partner launches YCANTH in Japan By Investing.com - Investing.com Nigeria
Verrica Pharmaceuticals stock rises after partner launches YCANTH in Japan - Investing.com
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical - The Manila Times
New molluscum treatment YCANTH reaches Japanese patients after Phase 3 trial - Stock Titan
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded to Hold Rating by Wall Street Zen - Defense World
Verrica Pharmaceuticals appoints Rosenberg as CMO - MSN
ETF Watch: Can Verrica Pharmaceuticals Inc continue delivering strong returnsWeekly Trading Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Verrica Pharmaceuticals (VRCA) upgraded to strong buy: Here's why - MSN
Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's Why - sharewise.com
Institution Moves: What hedge funds are buying Verrica Pharmaceuticals IncTrade Exit Summary & Reliable Price Action Trade Plans - baoquankhu1.vn
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Rally Mode: What is the PEG ratio of Intellicheck Inc2025 Fundamental Recap & Smart Allocation Stock Reports - baoquankhu1.vn
Sovran Advisors LLC Trims Holdings in Verrica Pharmaceuticals Inc. $VRCA - MarketBeat
Investor Alert: Common Warts Market Set for Rapid Growth – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Portfolio Recap: How does KeyCorp perform in inflationary periodsEarnings Trend Report & AI Powered Market Trend Analysis - baoquankhu1.vn
Verrica doses first patient in phase 3 wart trial, eyes major label expansion - MSN
YCANTH Phase 3 Wart Study Puts Verrica in Focus While Veeva Extends Its Clinical Footprint - TipRanks
Verrica’s VP-102 Advances Dermatology Care: First Patient Dosed in Global Phase 3 Common Warts Program - Barchart.com
Aug PreEarnings: Is Verrica Pharmaceuticals Inc stock a value trapMarket Risk Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded to “Buy” at Wall Street Zen - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Market Fear: Is Verrica Pharmaceuticals Inc stock a value trapAnalyst Downgrade & Daily Chart Pattern Signals - baoquankhu1.vn
Trade Report: Is Verrica Pharmaceuticals Inc stock good for income investorsPortfolio Gains Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences - MSN
Volume Recap: What is Life Time Group Holdings Incs P E ratio telling usJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11% - sharewise.com
Verrica Pharmaceuticals Reports Q4 2024 Growth and Pipeline Progress - MSN
Verrica Pharmaceuticals Appoints Dr. Noah Rosenberg as Chief Medical Officer - MSN
Will Verrica Pharmaceuticals Inc. stock see insider buyingTrade Analysis Report & High Win Rate Trade Alerts - ulpravda.ru
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $17.00 Consensus Target Price from Brokerages - Defense World
Verrica Doses First Patient in Phase 3 Wart Trial, Eyes Major Label Expansion - MyChesCo
Why Verrica Pharmaceuticals Inc. stock is favored by top institutionsJuly 2025 Snapshot & Free Safe Entry Trade Signal Reports - ulpravda.ru
Will Verrica Pharmaceuticals Inc. stock benefit from green energy trendsRisk Management & Free Daily Entry Point Trade Alerts - ulpravda.ru
Will Verrica Pharmaceuticals Inc. (1NE) stock outperform benchmarks2025 Major Catalysts & Accurate Trade Setup Notifications - Улправда
Verrica doses first patient in phase 3 trial for common wart treatment - Investing.com Nigeria
First Patient Dosed in Phase 3 VP-102 Common Warts Program - Dermatology Times
Verrica Pharmaceuticals stock advances as TD Cowen reiterates Buy rating By Investing.com - Investing.com Nigeria
Verrica Pharmaceuticals stock advances as TD Cowen reiterates Buy rating - Investing.com
Verrica Pharmaceuticals announces first patient dosed in phase 3 program - MarketScreener
Verrica Pharmaceuticals (VRCA) Begins Phase 3 Trials for Common Warts Treatment - GuruFocus
Verrica doses first patient in phase 3 trial for common wart treatment By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts - GlobeNewswire
0.95%
1.09%
자본화:
|
볼륨(24시간):